Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cilofexor Clear all
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

NCT03987074
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Semaglutide, Firsocostat, Cilofexor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Chandler, Arizona • Coronado, California • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 20, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT04971785
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), PTM SEMA, PTM CILO/FIR
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
175
States / cities
Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 137 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 20, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

NCT02943460
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Cilofexor, Placebo to match cilofexor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
16
States / cities
Sacramento, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 20, 2026, 8:02 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis

NCT02943447
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Cilofexor, Placebo to match cilofexor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
13
States / cities
Sacramento, California • Aurora, Colorado • Lakewood Rch, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 20, 2026, 8:02 AM EDT
Terminated Phase 1 Interventional Results available

Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

NCT04060147
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Compensated Cirrhosis
Interventions
Cilofexor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
16
States / cities
Chandler, Arizona • Pasadena, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 20, 2026, 8:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics

NCT02654002
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Cilofexor, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 20, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT03449446
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
SEL, FIR, CILO, Placebo to match FIR, Placebo to match CILO, Placebo to match SEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
81
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 20, 2026, 8:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function

NCT02808312
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)
Interventions
Cilofexor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 20, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)

NCT02781584
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions
SEL, FIR, CILO, FENO, VAS
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
12
States / cities
Chandler, Arizona • La Jolla, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 20, 2026, 8:02 AM EDT
Terminated Phase 3 Interventional Results available

Study of Cilofexor in Adults With Primary Sclerosing Cholangitis

NCT03890120
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Cilofexor, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
82
States / cities
Glendale, Arizona • Phoenix, Arizona • Coronado, California + 65 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 20, 2026, 8:02 AM EDT